BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ardissino G, Wally Ossola M, Maria Baffero G, Rigotti A, Cugno M. Eculizumab for Atypical Hemolytic Uremic Syndrome in Pregnancy. Obstetrics & Gynecology 2013;122:487-9. [DOI: 10.1097/aog.0b013e31828e2612] [Cited by in Crossref: 54] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Yu XJ, Yu F, Song D, Wang SX, Song Y, Liu G, Zhao MH. Clinical and renal biopsy findings predicting outcome in renal thrombotic microangiopathy: a large cohort study from a single institute in China. ScientificWorldJournal 2014;2014:680502. [PMID: 25184151 DOI: 10.1155/2014/680502] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
2 Kaplan BS, Ruebner RL, Spinale JM, Copelovitch L. Current treatment of atypical hemolytic uremic syndrome. Intractable Rare Dis Res. 2014;3:34-45. [PMID: 25343125 DOI: 10.5582/irdr.2014.01001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
3 Sarno L, Tufano A, Maruotti GM, Martinelli P, Balletta MM, Russo D. Eculizumab in pregnancy: a narrative overview. J Nephrol 2019;32:17-25. [PMID: 30159857 DOI: 10.1007/s40620-018-0517-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
4 Duran MN, Beyazit F, Erbaş M, Özkavak O, Acar C, Bakirdogen S. Successful treatment with eculizumab in a patient with pregnancy-associated atypical hemolytic uremic syndrome. Obstet Med. [DOI: 10.1177/1753495x211019902] [Reference Citation Analysis]
5 Özdemir H, Alkanat M. Nursing Care in Postpartum Atypical Hemolytic Uremic Syndrome: A Case Report. Clinical and Experimental Health Sciences. [DOI: 10.33808/clinexphealthsci.703341] [Reference Citation Analysis]
6 Davin JC, van de Kar NC. Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Ther Adv Hematol 2015;6:171-85. [PMID: 26288712 DOI: 10.1177/2040620715577613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
7 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
8 Rondeau E, Ardissino G, Caby-Tosi MP, Al-Dakkak I, Fakhouri F, Miller B, Scully M; Global aHUS Registry. Pregnancy in Women with Atypical Hemolytic Uremic Syndrome. Nephron 2021;:1-10. [PMID: 34515154 DOI: 10.1159/000518171] [Reference Citation Analysis]
9 Keating GM. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs. 2013;73:2053-2066. [PMID: 24249647 DOI: 10.1007/s40265-013-0147-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
10 Fontana F, Alfano G, Bardhushi E, Ligabue G, Giovanella S, Neri I, Cappelli G. Relapse of Atypical Hemolytic Uremic Syndrome During Pregnancy in a Patient on Eculizumab Maintenance Treatment: A Case Report. Am J Case Rep 2019;20:1460-5. [PMID: 31582717 DOI: 10.12659/AJCR.916994] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
11 Palma LM, Langman CB. Critical appraisal of eculizumab for atypical hemolytic uremic syndrome. J Blood Med 2016;7:39-72. [PMID: 27110144 DOI: 10.2147/JBM.S36249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
12 Vaught AJ, Gavriilaki E, Hueppchen N, Blakemore K, Yuan X, Seifert SM, York S, Brodsky RA. Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome. Exp Hematol 2016;44:390-8. [PMID: 26921648 DOI: 10.1016/j.exphem.2016.01.005] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 9.5] [Reference Citation Analysis]
13 Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S. An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document. Nefrología (English Edition) 2015;35:421-47. [DOI: 10.1016/j.nefroe.2015.11.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
14 Sheerin NS, Glover E. Haemolytic uremic syndrome: diagnosis and management. F1000Res 2019;8:F1000 Faculty Rev-1690. [PMID: 31598213 DOI: 10.12688/f1000research.19957.1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
15 Tsai HM, Kuo E. Eculizumab therapy leads to rapid resolution of thrombocytopenia in atypical hemolytic uremic syndrome. Adv Hematol 2014;2014:295323. [PMID: 25400666 DOI: 10.1155/2014/295323] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
16 Aminimoghaddam S, Afrooz N, Nasiri S, Motaghi Nejad O, Mahmoudzadeh F. A COVID-19 pregnant patient with thrombotic thrombocytopenic purpura: a case report. J Med Case Rep 2021;15:104. [PMID: 33648584 DOI: 10.1186/s13256-020-02577-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Cadet B, Meshoyrer D, Kim Z. Atypical hemolytic uremic syndrome: when pregnancy leads to lifelong dialysis: a case report and literature review. Cardiovasc Endocrinol Metab 2021;10:225-30. [PMID: 34765894 DOI: 10.1097/XCE.0000000000000247] [Reference Citation Analysis]
18 Wijnsma KL, Ter Heine R, Moes DJAR, Langemeijer S, Schols SEM, Volokhina EB, van den Heuvel LP, Wetzels JFM, van de Kar NCAJ, Brüggemann RJ. Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab. Clin Pharmacokinet 2019;58:859-74. [PMID: 30758736 DOI: 10.1007/s40262-019-00742-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 19.0] [Reference Citation Analysis]
19 Asif A, Nayer A, Haas CS. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol 2017;30:347-62. [PMID: 27848226 DOI: 10.1007/s40620-016-0357-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
20 Vester U, Mache CJ. Pharmacological treatment of atypical hemolytic-uremic syndrome. Expert Opinion on Orphan Drugs 2014;2:123-35. [DOI: 10.1517/21678707.2014.872029] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
21 Hussein W, Lafayette RA. Renal function in normal and disordered pregnancy. Curr Opin Nephrol Hypertens 2014;23:46-53. [PMID: 24247824 DOI: 10.1097/01.mnh.0000436545.94132.52] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
22 Mourad M, Jain J, Mehta MP, Feinberg BB, Burwick RM. Are We Getting Closer to Explaining Preeclampsia? Curr Obstet Gynecol Rep 2016;5:264-72. [DOI: 10.1007/s13669-016-0169-8] [Reference Citation Analysis]
23 Alrahmani L, Willrich MAV. The Complement Alternative Pathway and Preeclampsia. Curr Hypertens Rep 2018;20:40. [PMID: 29717384 DOI: 10.1007/s11906-018-0836-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
24 Román E, Mendizábal S, Jarque I, de la Rubia J, Sempere A, Morales E, Praga M, Ávila A, Górriz JL. Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option. Nefrología (English Edition) 2017;37:478-91. [DOI: 10.1016/j.nefroe.2017.08.001] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
25 Edens C, Rodrigues BC, Lacerda MI, Dos Santos FC, De Jesús GR, De Jesús NR, Levy RA, Leatherwood C, Mandel J, Bermas B. Challenging cases in rheumatic pregnancies. Rheumatology (Oxford) 2018;57:v18-25. [PMID: 30137591 DOI: 10.1093/rheumatology/key172] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Demir E, Yazici H, Ozluk Y, Kilicaslan I, Turkmen A. Pregnant Woman with Atypical Hemolytic Uremic Syndrome Delivered a Healthy Newborn under Eculizumab Treatment. Case Rep Nephrol Dial 2016;6:143-8. [PMID: 28101502 DOI: 10.1159/000454946] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
27 Bruel A, Kavanagh D, Noris M, Delmas Y, Wong EKS, Bresin E, Provôt F, Brocklebank V, Mele C, Remuzzi G, Loirat C, Frémeaux-Bacchi V, Fakhouri F. Hemolytic Uremic Syndrome in Pregnancy and Postpartum. Clin J Am Soc Nephrol 2017;12:1237-47. [PMID: 28596415 DOI: 10.2215/CJN.00280117] [Cited by in Crossref: 86] [Cited by in F6Publishing: 37] [Article Influence: 17.2] [Reference Citation Analysis]
28 Gaggl M, Aigner C, Csuka D, Szilágyi Á, Prohászka Z, Kain R, Haninger N, Knechtelsdorfer M, Sunder-Plassmann R, Sunder-Plassmann G, Schmidt A. Maternal and Fetal Outcomes of Pregnancies in Women with Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol 2018;29:1020-9. [PMID: 29282226 DOI: 10.1681/ASN.2016090995] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 5.6] [Reference Citation Analysis]
29 Stefanovic V. The Extended Use of Eculizumab in Pregnancy and Complement Activation⁻Associated Diseases Affecting Maternal, Fetal and Neonatal Kidneys-The Future Is Now? J Clin Med 2019;8:E407. [PMID: 30909646 DOI: 10.3390/jcm8030407] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
30 Duval A, Olagne J, Cognard N, Gautier Vargas G, Joly M, Perrin P, Fritz G, Fourtage M, Moulin B, Caillard S. Pregnancy in a Kidney Transplant Woman Under Treatment With Eculizumab for Atypical Hemolytic Uremic Syndrome: Is It Safe? Kidney Int Rep 2019;4:733-9. [PMID: 31080930 DOI: 10.1016/j.ekir.2018.12.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
31 Socié G, Caby-Tosi MP, Marantz JL, Cole A, Bedrosian CL, Gasteyger C, Mujeebuddin A, Hillmen P, Vande Walle J, Haller H. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol 2019;185:297-310. [PMID: 30768680 DOI: 10.1111/bjh.15790] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 20.7] [Reference Citation Analysis]
32 Sharma R, Keyzner A, Liu J, Bradley T, Allen SL. Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis. Leuk Res Rep 2015;4:36-8. [PMID: 26052501 DOI: 10.1016/j.lrr.2015.05.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
33 Blasco M, Guillén E, Quintana LF, Garcia-Herrera A, Piñeiro G, Poch E, Carreras E, Campistol JM, Diaz-Ricart M, Palomo M. Thrombotic microangiopathies assessment: mind the complement. Clin Kidney J 2021;14:1055-66. [PMID: 33841853 DOI: 10.1093/ckj/sfaa195] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Jim B, Garovic VD. Acute Kidney Injury in Pregnancy. Semin Nephrol 2017;37:378-85. [PMID: 28711077 DOI: 10.1016/j.semnephrol.2017.05.010] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 11.8] [Reference Citation Analysis]
35 Elabd H, Elkholi M, Steinberg L, Acharya A. Eculizumab, a novel potential treatment for acute kidney injury associated with preeclampsia/HELLP syndrome. BMJ Case Rep 2019;12:e228709. [PMID: 31492725 DOI: 10.1136/bcr-2018-228709] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]